This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia Open Access 26 August 2023
-
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
Clinical Epigenetics Open Access 12 April 2021
-
Aging and leukemic evolution of hematopoietic stem cells under various stress conditions
Inflammation and Regeneration Open Access 05 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Maciejewski JP, Mufti GJ . Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008; 112: 965–974.
Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182–6192.
Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109–6116.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.
Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP . UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia 2009; 23: 610–614.
Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 2010; 24: 216–219.
O'Keefe C, McDevitt MA, Maciejewski JP . Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood 2010; 115: 2731–2739.
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–185.
Acknowledgements
This work was supported in part by RO1HL-082983, K24 HL-077522, and by a grant from the AA&MDS International Foundation and Robert Duggan Charitable Fund (JPM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Makishima, H., Jankowska, A., Tiu, R. et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 24, 1799–1804 (2010). https://doi.org/10.1038/leu.2010.167
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.167
This article is cited by
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia (2023)
-
Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes
Molecular Biology Reports (2023)
-
Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia
Leukemia (2022)
-
Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients
Clinical Epigenetics (2021)
-
Aging and leukemic evolution of hematopoietic stem cells under various stress conditions
Inflammation and Regeneration (2020)